share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Atkinson Edward Morrow III

SEC announcement ·  Feb 28 05:50
Summary by Futu AI
Edward Morrow III, EVP and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two separate dates. On February 23, 2024, Morrow disposed of 1,654 shares at a price of $431.79 per share, followed by a sale of 883 shares on February 26, 2024, at $425.70 each. The transactions resulted in a total of 2,537 shares sold, with the combined sales amounting to approximately $1,090,073.76. After these transactions, Morrow's direct holdings in Vertex Pharmaceuticals totaled 15,972 shares.
Edward Morrow III, EVP and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two separate dates. On February 23, 2024, Morrow disposed of 1,654 shares at a price of $431.79 per share, followed by a sale of 883 shares on February 26, 2024, at $425.70 each. The transactions resulted in a total of 2,537 shares sold, with the combined sales amounting to approximately $1,090,073.76. After these transactions, Morrow's direct holdings in Vertex Pharmaceuticals totaled 15,972 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.